Jotin Marango, CFO/COO
Professional Overview
Jotin Marango is an experienced finance and operations executive with a proven track record of driving strategic growth and operational excellence in the biotechnology industry. As the current CFO/COO at Ikena Oncology, he leverages his expertise in financial management, business development, and cross-functional leadership to support the company's mission of developing innovative cancer therapeutics.
Experience Summary
Current Role
As the CFO/COO of Ikena Oncology since April 2022, Jotin is responsible for overseeing the company's financial strategy, capital planning, and operational efficiency. He plays a key role in aligning Ikena's financial resources with its R&D and business development initiatives, ensuring the organization remains well-positioned to achieve its long-term goals.
Career Progression
Prior to joining Ikena Oncology, Jotin served as the CFO/CBO at Aptose Biosciences, Inc., where he successfully led the company's financial and business operations from May 2019 to April 2022. In this role, he was instrumental in securing funding, optimizing resource allocation, and cultivating strategic partnerships to support Aptose's development of novel cancer therapeutics.
Academic Background
Jotin holds a Bachelor of Science degree in Finance and Accounting from a leading university, where he graduated with distinction and demonstrated exceptional academic performance.
Areas of Expertise
- Financial management and planning
- Business development and strategic partnerships
- Operational optimization and cross-functional leadership
- Biopharmaceutical industry knowledge and regulatory compliance
- Mergers, acquisitions, and capital markets transactions
Professional Impact
Throughout his career, Jotin has made significant contributions to the success of his previous employers. At Aptose Biosciences, he played a pivotal role in securing over $100 million in funding to support the company's research and development efforts, ultimately advancing multiple drug candidates into clinical trials. His strategic financial management and operational expertise have been instrumental in driving Ikena Oncology's growth and positioning the company for continued success in the highly competitive oncology market.
Conclusion
With his extensive experience in the biopharmaceutical industry, proven track record of financial leadership, and commitment to operational excellence, Jotin Marango is well-equipped to contribute to Ikena Oncology's mission of developing transformative cancer therapies. His versatile skill set and strategic mindset make him a valuable asset to the organization as it navigates the challenges and opportunities in the rapidly evolving oncology landscape.
